IFN‐ γ Levels and Indeterminate Rate: Comparative Analysis of Three Commercial Interferon‐Gamma Release Assays for Diagnosis of Mycobacterium tuberculosis Infection
Authors:
- Richard KutameRKRichard Kutame
- Gifty BoatengGBGifty Boateng
- Vincent Gyau BoatengVBVincent Gyau Boateng
- Florence Agyemang-BiohFAFlorence Agyemang-Bioh
- Lorreta AntwiLALorreta Antwi
- Patricia YankeyPYPatricia Yankey
- Valerie Lucy Naa Aku VanderpuyeVVValerie Lucy Naa Aku Vanderpuye
- Joycelene Akua AttuJAJoycelene Akua Attu
- Baakwa De-Graft MiahBMBaakwa De-Graft Miah
- Nathan Kofi AntwiNANathan Kofi Antwi
- Alice BoakyewaaABAlice Boakyewaa
- Rexford AdadeRARexford Adade
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Advances in Public Health
- Vol. 2026 (1)
Abstract
Background: The diagnosis of Mycobacterium tuberculosis infection increasingly relies on interferon‐gamma release assay (IGRA) technologies. Despite their usefulness, inconsistency in IFN‐ γ responses and the persistence of indeterminate results remain problematic across IGRA platforms. The present study aimed to comparatively assess three commercial IGRA assays (TBF‐ELISA, TBF‐FIA, and QFT‐Plus) with emphasis on IFN‐ γ production and factors influencing indeterminate results. Methods: The study employed a cross‐sectional design and was implemented at the National Public Health and Reference Laboratory in Ghana. A total of 1148 individuals were enrolled consecutively and stratified according to their TB exposure status. Parallel testing of collected blood samples was performed with the three IGRA assays. IFN‐ γ production was quantified, and the rate of indeterminate results was analyzed. Multivariate regression analyses were performed to assess determinants of IFN‐ γ levels and indeterminate results. Results: Significant quantitative differences in IFN‐ γ responses were observed across platforms ( p < 0.001). Active TB was the strongest predictor of IFN‐ γ release, with highest mean levels detected by TBF‐FIA (6.18 IU/mL), followed by TBF‐ELISA (3.11 IU/mL) and QFT‐Plus (2.80–2.96 IU/mL). TBF‐ELISA showed strong concordance with minimal bias versus QFT‐Plus (≤0.167 IU/mL), whereas TBF‐FIA demonstrated substantial proportional bias (>1.5 IU/mL). Indeterminate rates differed significantly (TBF‐FIA 13%, QFT‐Plus 8%, TBF‐ELISA 6%; Cochran’s Q test, p < 0.001). Demographic factors were not associated with assay failure; however, sample collection sites were significantly related. Notably, healthcare workers and TB contacts showed lower IFN‐ γ responses than expected. Conclusion: While all three IGRAs effectively differentiate TB infection status, the variability in IFN‐ γ responses and indeterminate rates is an indication that they may not be interchangeable. TBF‐FIA demonstrated the highest variability, requiring further investigation. The findings suggest that each test has its own strengths and limitations, thus, the need for selective use depending on the clinical setting and testing purpose.Keywords
This publication has 28 references indexed in Scilit:
- Diagnostic accuracy study of STANDARD TB-Feron FIA and STANDARD TB-Feron ELISA tests for tuberculosis infection diagnosis in Eastern European settingJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2025
- Analysis of Indeterminate QuantiFERON Assay Results in Solid Organ Transplant Candidates and Proposed Management AlgorithmTransplantation, 2024
- Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: a systematic review and meta-analysisClinical Microbiology and Infection, 2023
- Evaluation of Standard E TB-Feron Enzyme-Linked Immunosorbent Assay for Diagnosis of Latent Tuberculosis Infection in Health Care WorkersJournal of Clinical Microbiology, 2019
- Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis InfectionOpen Forum Infectious Diseases, 2018
- Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care WorkersJournal of Clinical Microbiology, 2018
- First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB PlusJournal of Infection, 2016
- Evaluation of QuantiFERON-TB Gold Plus for Detection of Mycobacterium tuberculosis infection in JapanScientific Reports, 2016
- Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseasesRheumatology International, 2014
- Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensorTuberculosis, 2012